|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/04/22 Passage BIO, Inc. 10-Q 6/30/22 58:6.6M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.86M
2: EX-10.1 Material Contract HTML 87K
3: EX-10.2 Material Contract HTML 42K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 19K
13: R1 Document and Entity Information HTML 73K
14: R2 Balance Sheets HTML 107K
15: R3 Balance Sheets (Parenthetical) HTML 25K
16: R4 Statements of Operations and Comprehensive Loss HTML 71K
17: R5 Statements of Stockholders' Equity HTML 84K
18: R6 Statements of Stockholders' Equity (Parenthetical) HTML 18K
19: R7 Statements of Cash Flows HTML 103K
20: R8 Nature of Operations HTML 21K
21: R9 Risks and Liquidity HTML 22K
22: R10 Summary of Significant Accounting Policies HTML 40K
23: R11 Cash, cash equivalents and marketable securities HTML 111K
24: R12 Fair Value of Financial Instruments HTML 112K
25: R13 Property and Equipment, net HTML 36K
26: R14 Accrued Expenses and Other Current Liabilities HTML 32K
27: R15 Leases HTML 54K
28: R16 Commitments and Contingencies HTML 32K
29: R17 Share-Based Compensation HTML 99K
30: R18 Subsequent Events HTML 20K
31: R19 Summary of Significant Accounting Policies HTML 61K
(Policies)
32: R20 Summary of Significant Accounting Policies HTML 28K
(Tables)
33: R21 Cash, cash equivalents and marketable securities HTML 112K
(Tables)
34: R22 Fair Value of Financial Instruments (Tables) HTML 108K
35: R23 Property and Equipment, net (Tables) HTML 34K
36: R24 Accrued Expenses and Other Current Liabilities HTML 32K
(Tables)
37: R25 Leases (Tables) HTML 49K
38: R26 Share-Based Compensation (Tables) HTML 96K
39: R27 Risks and Liquidity (Details) HTML 30K
40: R28 Summary of Significant Accounting Policies HTML 35K
(Details)
41: R29 Cash, cash equivalents and marketable securities - HTML 31K
Portfolio of Cash and Cash Equivalents (Details)
42: R30 Cash, cash equivalents and marketable securities - HTML 43K
Portfolio of Marketable Securities (Details)
43: R31 Fair Value of Financial Instruments (Details) HTML 55K
44: R32 Property and Equipment, net (Details) HTML 39K
45: R33 Accrued Expenses and Other Current Liabilities HTML 30K
(Details)
46: R34 Leases (Details) HTML 80K
47: R35 Leases - Operating lease cost (Details) HTML 26K
48: R36 Commitments and Contingencies - Collaboration HTML 65K
Agreements (Details)
49: R37 Share-Based Compensation - Equity Incentive Plan & HTML 62K
ESPP (Details)
50: R38 Share-Based Compensation - Share-based HTML 28K
compensation expense (Details)
51: R39 Share-Based Compensation - Stock Option Activity HTML 67K
(Details)
52: R40 Share-Based Compensation - Assumptions Used in HTML 25K
Determining Fair Value & Early exercise of Stock
Options (Details)
53: R41 Share-Based Compensation - Restricted Stock Units HTML 46K
(Details)
56: XML IDEA XML File -- Filing Summary XML 97K
54: XML XBRL Instance -- pasg-20220630x10q_htm XML 1.41M
55: EXCEL IDEA Workbook of Financial Reports XLSX 92K
9: EX-101.CAL XBRL Calculations -- pasg-20220630_cal XML 116K
10: EX-101.DEF XBRL Definitions -- pasg-20220630_def XML 316K
11: EX-101.LAB XBRL Labels -- pasg-20220630_lab XML 905K
12: EX-101.PRE XBRL Presentations -- pasg-20220630_pre XML 597K
8: EX-101.SCH XBRL Schema -- pasg-20220630 XSD 121K
57: JSON XBRL Instance as JSON Data -- MetaLinks 270± 415K
58: ZIP XBRL Zipped Folder -- 0001558370-22-012042-xbrl Zip 463K
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Simona King, Chief Financial Officer of Passage Bio, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | |
Dated: August 4, 2022 | /s/ | |
Chief Financial Officer | ||
(Principal Financial Officer and Principal Accounting Officer) | ||
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/4/22 | None on these Dates | ||
| For Period end: | 6/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/04/24 Passage BIO, Inc. 10-K 12/31/23 73:10M Toppan Merrill Bridge/FA 3/06/23 Passage BIO, Inc. 10-K 12/31/22 70:9M Toppan Merrill Bridge/FA |